Navigation Links
Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
Date:1/23/2013

ST. LOUIS, Jan. 23, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) will hold its quarterly conference call to discuss fourth quarter and full-year 2012 results on Thursday, February 7, 2013, at 11:00 AM Eastern Time.

Conference call details:
Date: February 7, 2013
Time: 11:00 AM ET

Listen via Internet: http://investor.sigmaaldrich.com/
Telephone: 877-266-0483
International: 707-287-9342

A replay of the call will be available from 2/07/2013 to 2/14/2013. For replay, please call: Domestic: 855-859-2056 International: 404-537-3406; Conference ID#: 93187749.

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company.  Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.  The Company has customers in life science companies, university and government institutions, hospitals and industry.  Over one million scientists and technologists use its products.  Sigma-Aldrich operates in 38 countries and has 9,000 employees providing excellent service worldwide.  The Company is committed to accelerating customer success through innovation and leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit its award winning web site at www.sigma-aldrich.com.

 


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sigma-Aldrich Elects Michael Marberry As Director
2. Sigma-Aldrich Corporation Announces New Credit Facility
3. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
4. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
5. Oramed Pharmaceuticals Announces Reverse Stock Split
6. Kenrico Announces Records of Patents for 2012 and Financial Targets for 2013
7. Cato Research and Cato BioVentures Announces the Opening of Houston, Texas, Office
8. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
9. NSG Announces New Quartz Micro Flow Channel
10. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
11. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamberâ„¢ for conduct of Allergy & Asthma Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... , Feb. 16, 2017 UCHealth ( ... utilize LungDirect for pulmonary nodule patient management. In addition ... or a spot on the lung, UCHealth looks to ... manual data entry. Stephanie Brown, RN ... my nodule patients with an Excel spreadsheet, which was ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):